CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

As is known, diet plays a crucial role in managing blood sugar levels, especially in people with diabetes. Speaking with the OnlyMyHealth team, Edwina Raj, Head of Services – Clinical Nutrition ...

Infection, delayed kidney function, kidney loss and death are all risks associated with kidney transplant surgery in obese ...

Classically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned with that of injectable GLP-1 therapies, according to ...

Eli Lilly and Co. (LLY) announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa ...

Energy drinks are known for their energy-boosting effects. However, they can adversely affect various body systems and ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...